Low IMA Ligation Did Not Significantly Reduce Leaks - Summary - MDSpire
Advertisement
Low IMA Ligation Did Not Significantly Reduce Leaks
A randomized trial found similar short-term morbidity and 12-month functional outcomes with both approaches, while highlighting the need to balance perfusion with a tension-free anastomosis.
To compare the rates of symptomatic anastomotic leakage and patient-reported outcomes between low and high inferior mesenteric artery ligation in minimally invasive rectal cancer surgery.
Approach:
Study Design: A multicenter, prospective, randomized clinical trial conducted at 7 tertiary hospitals in South Korea from July 2019 to August 2024.
Participants: 314 randomized patients aged 18 to 80 years with histologically confirmed clinical stage I to III primary rectal adenocarcinoma scheduled for minimally invasive anterior resection.
Intervention: Patients were assigned to either low ligation (inferior mesenteric artery divided distal to the left colic artery) or high ligation (within 2 cm of the artery’s origin).
Endpoints: Primary endpoint was symptomatic grade B or C anastomotic leakage within 30 days post-surgery.
Key Findings:
Symptomatic anastomotic leakage occurred in 5% of low ligation patients and 6% of high ligation patients, with no statistically significant difference.
No significant differences in overall 30-day morbidity or most patient-reported outcomes at 12 months.
The trial was underpowered to detect smaller differences due to lower than expected leakage rates.
Interpretation:
Limitations:
The study may have been underpowered due to lower observed leakage rates than anticipated.
Long-term cancer recurrence and survival were not assessed.
The proportion of patients receiving neoadjuvant chemoradiotherapy was lower than typical in Western practice.
Older patients with documented cognitive impairment also experienced greater postoperative functional decline following elective total knee arthroplasty
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.